Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/12/26
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)GlobeNewsWire • 05/12/26
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast CancerGlobeNewsWire • 05/01/26
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 DaysGlobeNewsWire • 03/18/26
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersGlobeNewsWire • 03/11/26
Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/10/26
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/24/26
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026GlobeNewsWire • 02/17/26
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and DirectorGlobeNewsWire • 02/12/26
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and ExpositionGlobeNewsWire • 12/06/25
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)GlobeNewsWire • 11/24/25
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/05/25